Sanofi Company Profile

What is the competitive landscape for SANOFI

SANOFI has one hundred and twenty-four approved drugs.

There are eleven US patents protecting SANOFI drugs.

There are two hundred and thirty-eight patent family members on SANOFI drugs in fifty-three countries and one hundred and eighteen supplementary protection certificates in nineteen countries.

Summary for Sanofi

International Patents:	238
US Patents:	11
Tradenames:	99
Ingredients:	88
NDAs:	124
Patent Litigation for Sanofi:	See patent lawsuits for Sanofi
PTAB Cases with Sanofi as petitioner:	See PTAB cases with Sanofi as petitioner

Drugs and US Patents for Sanofi

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-002	Jul 6, 1988		DISCN	No	No
Sanofi Aventis Us	METATENSIN #4	reserpine; trichlormethiazide	TABLET;ORAL	012972-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	DIABETA	glyburide	TABLET;ORAL	017532-003	May 1, 1984	AB2	RX	Yes	Yes
Sanofi Aventis Us	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER	milrinone lactate	INJECTABLE;INJECTION	020343-001	Aug 9, 1994		DISCN	Yes	No
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Sanofi

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-002	Sep 10, 1998	4,351,841
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-002	Sep 12, 2012	5,679,709
Sanofi Aventis Us	DIABETA	glyburide	TABLET;ORAL	017532-002	May 1, 1984	3,454,635
Sanofi	RENVELA	sevelamer carbonate	TABLET;ORAL	022127-001	Oct 19, 2007	6,509,013
Sanofi Aventis Us	DIABETA	glyburide	TABLET;ORAL	017532-003	May 1, 1984	3,426,067

Paragraph IV (Patent) Challenges for SANOFI drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	200 mg/40 mL		2007-07-16
	Injection	100 mg/mL, 3 mL vials		2006-12-07
	Tablets	150 mg/12.5 mg and 300 mg/12.5 mg		2004-11-10
	Tablets	75 mg, 150 mg and 300 mg		2004-05-25
	Capsules	0.5 mcg and 2.5 mcg		2009-03-25
	Tablets	300 mg		2009-03-04
	Capsules	1 mcg		2010-02-12
	Tablets	800 mg		2008-12-04
	Injection	40 mg/mL, 0.5 mL and 2 mL vials		2009-06-30
	For Injection	50 mg/vial and 100 mg/vial		2007-02-09
	Injection	5 mg/mL, 40 mL vial		2011-03-23
	Tablets	7 mg and 14 mg		2016-09-12
	Tablets	300 mg/25 mg		2006-06-06
	Capsules	0.4 mg		2004-12-20
	Tablets	400 mg		2013-07-01
	Injection	2 mcg/mL, 2 mL ampules		2007-10-15
	Injection	2 mcg/mL, 1 mL in 2 mL vial		2011-12-28
	Powder for Oral Suspension	0.8 g/packet and 2.4 g/packet		2009-12-30
	Injection	5 mg/mL, 10 mL and 20 mL vials		2007-02-09

International Patents for Sanofi Drugs

Country	Patent Number	Estimated Expiration
Norway	2015013
Colombia	6260064
Malaysia	153608
Denmark	1667986
South Korea	20120093986

Supplementary Protection Certificates for Sanofi Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1381356	C01381356/01	Switzerland		FORMER OWNER: AVENTISUB LLC, US
1381356	92366	Luxembourg		PRODUCT NAME: TERIFLUNOMIDE,SON STEREOISOMERE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES
1381356	8/2014	Austria		PRODUCT NAME: TERIFLUNOMID, SEINE STEREOISOMERE AND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/13/838 20130826
0281459	35/1998	Austria		PRODUCT NAME: CLOPIDOGREL-HYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/98/069/001 - EU/1/98/069/003 19980715
1667986	C01667986/01	Switzerland		PRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: SWISSMEDIC 61543 06.04.2011

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Sanochemia Corp Usa
• Sanofi
• Sanofi Aventis Us

Pharmaceutical Competitive Landscape Analysis: Sanofi – Market Position, Strengths & Strategic Insights

Last updated: February 12, 2025

In the ever-evolving pharmaceutical industry, Sanofi has emerged as a formidable player, consistently demonstrating its ability to adapt and thrive in a competitive landscape. As we delve into Sanofi's market position, strengths, and strategic insights, we'll uncover the factors that have propelled this pharmaceutical giant to the forefront of the industry.

Sanofi's Market Position

Sanofi has solidified its position as one of the top pharmaceutical companies globally. As of 2024, Sanofi ranks as the eighth largest pharmaceutical company in the world by revenue[2]. This impressive standing is a testament to the company's robust product portfolio and strategic growth initiatives.

Global Presence and Market Share

With operations spanning over 170 countries, Sanofi boasts a truly global footprint[8]. This extensive reach allows the company to tap into diverse markets and maintain a strong presence across various regions. In 2022, Sanofi held approximately 3.8% of the global pharmaceutical market share[5], demonstrating its significant influence in the industry.

Key Markets and Revenue Distribution

Sanofi's revenue distribution highlights its strategic focus on key markets:

• United States: 35% of revenue
• Europe: 25% of revenue
• Emerging Markets: 20% of revenue[5]

This balanced approach allows Sanofi to capitalize on established markets while also tapping into the growth potential of emerging economies.

Sanofi's Strengths and Competitive Advantages

Sanofi's success can be attributed to several key strengths that set it apart from its competitors.

Diverse Product Portfolio

One of Sanofi's primary strengths lies in its diverse portfolio of pharmaceuticals, vaccines, and consumer healthcare products[3]. This broad range of offerings allows the company to:

1. Cater to a wide spectrum of patient needs
2. Address multiple therapeutic areas
3. Adapt to changing market dynamics
4. Mitigate risks associated with dependence on a single product or therapeutic area

Focus on Research and Development

Sanofi demonstrates a strong commitment to research and development (R&D), consistently investing in innovation and advancement in healthcare solutions. In 2020, Sanofi invested over €5.9 billion in R&D[3], showcasing its dedication to staying at the forefront of medical advancements.

"2023 was a turning-point year for Sanofi, paving the way for our scientific leadership in Immunology. Coupled with our AI at-scale ambitions, we go forward as a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth" - Paul Hudson, CEO of Sanofi[2]

This focus on R&D has enabled Sanofi to:

• Develop new treatments and therapies
• Address various health conditions
• Improve patient outcomes
• Maintain a competitive edge in the industry

Strong Market Presence in Key Therapeutic Areas

Sanofi has established a strong presence in several key therapeutic areas, including:

1. Diabetes care: 7.2% market share
2. Vaccine market: 6.5% market share[5]

These significant market shares in crucial areas contribute to Sanofi's overall competitive position and revenue growth.

Strategic Initiatives and Future Outlook

Sanofi has implemented several strategic initiatives to drive growth and maintain its competitive edge in the pharmaceutical industry.

Play to Win Strategy

In October 2023, Sanofi provided a comprehensive update on its Play to Win strategy, which focuses on:

1. Executing transformative medicine and vaccine launches
2. Driving agile and efficient resource deployment
3. Enhancing R&D productivity[4]

As part of this strategy, Sanofi announced plans to increase its R&D investments to fully realize its pipeline potential and drive long-term growth.

Consumer Healthcare Business Separation

Sanofi has announced its intention to separate its Consumer Healthcare Business, enabling greater management focus and resource allocation to the Biopharma business[4]. This strategic move is expected to create value-creating opportunities and longer-term operational levers to support accelerated R&D investments.

Focus on Immunology and Neuro-inflammation

Sanofi is developing an industry-leading immunology and strong neuro-inflammation pipeline, with currently 7 assets in mid- to late-stage development. Each of these assets has a peak sales potential of at least €2 to €5 billion[4], highlighting the company's commitment to addressing unmet medical needs in these areas.

Cost Savings and Reinvestment

To support its growth initiatives, Sanofi is executing a €2.7 billion cost savings plan. These savings will be reinvested in the company's growth drivers[4], ensuring a sustainable approach to long-term success.

Strategic Partnerships and Acquisitions

Sanofi has been actively pursuing strategic partnerships and acquisitions to strengthen its pipeline and enhance its technological capabilities. Some notable examples include:

1. A $140 million partnership with French tech company Aqemia to revolutionize drug discovery using physics algorithms and generative artificial intelligence[2].
2. Investing in over 25 value-creating business development and M&A deals to further strengthen Sanofi's pipeline[4].

Competitive Landscape and Industry Trends

To fully appreciate Sanofi's market position, it's essential to understand the competitive landscape and industry trends shaping the pharmaceutical sector.

Key Competitors

Sanofi operates in a highly competitive market, with several major players vying for market share. Some of Sanofi's key competitors include:

Competitor	Global Pharmaceutical Revenue 2022	Key Therapeutic Areas
Pfizer	$100.3 billion	Vaccines, Oncology, Rare Diseases
GlaxoSmithKline	$44.2 billion	Vaccines, Respiratory, HIV
Merck & Co	$57.9 billion	Oncology, Vaccines, Diabetes
Sanofi	$44.1 billion	Diabetes, Oncology, Rare Diseases

[5]

This competitive landscape drives innovation and encourages the development of new therapies, ultimately benefiting patients by providing a variety of treatment options.

Industry Trends Shaping the Future

Several key trends are shaping the future of the pharmaceutical industry, and Sanofi is positioning itself to capitalize on these opportunities:

1. AI-driven drug discovery
2. Clinical trials technology
3. Digital pharmacy tech
4. Digital therapeutics[9]

Sanofi is actively investing in and partnering with companies in these areas to stay ahead of the curve and drive innovation in drug development and patient care.

SWOT Analysis: Sanofi's Strengths, Weaknesses, Opportunities, and Threats

A comprehensive SWOT analysis provides valuable insights into Sanofi's current position and future prospects.

Strengths

1. Global presence in over 170 countries
2. Diverse product portfolio spanning multiple therapeutic areas
3. Strong focus on R&D and innovation
4. Established market leadership in key areas like diabetes care and vaccines
5. Robust pipeline of potential new molecular entities

Weaknesses

1. Dependence on key products like Dupixent for growth
2. Challenges in some legacy product lines
3. Exposure to patent expirations and generic competition

Opportunities

1. Expanding presence in emerging markets
2. Leveraging AI and technology for drug discovery and development
3. Growing demand for innovative treatments in areas like immunology and oncology
4. Potential for strategic acquisitions and partnerships

Threats

1. Intense competition from other pharmaceutical giants
2. Regulatory challenges and pricing pressures
3. Potential disruptions in global supply chains
4. Rapid technological advancements requiring continuous adaptation

Future Prospects and Growth Strategy

Looking ahead, Sanofi's future prospects appear promising, driven by its strategic initiatives and focus on key growth areas.

Accelerating R&D Investments

Sanofi's commitment to increasing R&D investments is expected to fuel long-term growth and enhance shareholder value. By focusing on high-value innovation, the company aims to deliver breakthrough science that improves people's lives[4].

Expanding in Key Therapeutic Areas

Sanofi's strong pipeline in immunology and neuro-inflammation, with 7 assets in mid- to late-stage development, positions the company for significant growth in these areas[4]. Each of these assets has the potential to generate substantial revenue, contributing to Sanofi's future success.

Leveraging Technology and AI

By embracing AI-driven drug discovery and other technological advancements, Sanofi is positioning itself as a development-driven, tech-powered biopharma company[2]. This focus on innovation is expected to accelerate growth and improve the efficiency of drug development processes.

Strategic Partnerships and Acquisitions

Sanofi's continued investment in value-creating business development and M&A deals is likely to strengthen its pipeline and expand its capabilities in key areas[4]. These strategic moves will help the company stay competitive and drive future growth.

Key Takeaways

1. Sanofi ranks as the eighth largest pharmaceutical company globally, with a strong presence in over 170 countries.
2. The company's diverse product portfolio and focus on R&D are key strengths driving its competitive advantage.
3. Sanofi's Play to Win strategy emphasizes increased R&D investments and focus on key therapeutic areas like immunology and neuro-inflammation.
4. The separation of the Consumer Healthcare Business is expected to create value and support accelerated R&D investments.
5. Sanofi is actively pursuing strategic partnerships and acquisitions to enhance its technological capabilities and strengthen its pipeline.
6. The company is well-positioned to capitalize on industry trends such as AI-driven drug discovery and digital therapeutics.
7. Future growth prospects are promising, driven by a strong pipeline and focus on high-value innovation.

FAQs

1. Q: What is Sanofi's global market share in the pharmaceutical industry? A: As of 2022, Sanofi held approximately 3.8% of the global pharmaceutical market share.

2. Q: How much does Sanofi invest in Research and Development? A: In 2020, Sanofi invested over €5.9 billion in R&D, demonstrating its strong commitment to innovation.

3. Q: What are Sanofi's key therapeutic areas? A: Sanofi focuses on several key therapeutic areas, including diabetes, oncology, immunology, and rare diseases.

4. Q: How is Sanofi leveraging artificial intelligence in its operations? A: Sanofi is partnering with companies to speed up drug discovery using AI and has formed a $140 million partnership with Aqemia to revolutionize drug discovery using physics algorithms and generative AI.

5. Q: What is Sanofi's Play to Win strategy? A: The Play to Win strategy focuses on executing transformative medicine and vaccine launches, driving agile resource deployment, and enhancing R&D productivity to drive long-term growth and innovation.

Sources cited: [1] https://www.sanofi.com/en/media-room/press-releases/2024/2024-07-25-05-30-00-2918503 [2] https://www.proclinical.com/blogs/2024-7/who-are-the-top-10-pharma-companies-in-the-world-2024 [3] https://blog.osum.com/sanofi-swot-analysis/ [4] https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-27-05-30-00-2768148 [5] https://dcfmodeling.com/products/sny-porters-five-forces-analysis [8] https://pitchgrade.com/companies/sanofi [9] https://www.cbinsights.com/research/sanofi-strategy-map-investments-partnerships/